News
RIGL
47.66
-0.99%
-0.48
Weekly Report: what happened at RIGL last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at RIGL last week (0907-0911)?
Weekly Report · 09/14 10:20
Analysts Are Bullish on These Healthcare Stocks: Rigel (RIGL), Opus Genetics (IRD)
TipRanks · 09/08 10:30
Weekly Report: what happened at RIGL last week (0831-0904)?
Weekly Report · 09/07 10:13
Weekly Report: what happened at RIGL last week (0824-0828)?
Weekly Report · 08/31 10:20
Weekly Report: what happened at RIGL last week (0817-0821)?
Weekly Report · 08/24 10:21
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)
Seeking Alpha · 08/19 08:14
Rigel Pharmaceuticals Is Maintained at Neutral by Piper Sandler
Dow Jones · 08/17 16:23
Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49
Benzinga · 08/17 16:13
Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler
TipRanks · 08/17 11:11
Weekly Report: what happened at RIGL last week (0810-0814)?
Weekly Report · 08/17 10:22
Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer
TipRanks · 08/17 07:53
Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright
TipRanks · 08/16 13:12
Rigel Pharmaceuticals Price Target Raised to $85.00/Share From $57.00 by HC Wainwright & Co.
Dow Jones · 08/14 17:47
Rigel Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/14 17:47
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85
Benzinga · 08/14 17:37
H.C. Wainwright Reaffirms Their Buy Rating on Rigel (RIGL)
TipRanks · 08/14 13:35
Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription
Benzinga · 08/13 12:13
Weekly Report: what happened at RIGL last week (0803-0807)?
Weekly Report · 08/10 10:17
Rigel Pharmaceuticals price target raised to $83 from $81 at Citi
TipRanks · 08/06 10:21
More
Webull provides a variety of real-time RIGL stock news. You can receive the latest news about Rigel Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.